Scott Rocklage became the managing partner of 5AM Ventures. Scott has over 20 years of experience in the health care field. Other companies that he has served in his illustrious career include Cubist Pharmaceuticals and Nycomed Interventional. He was the board chairman at Cubist and the CEO at Nycomed. Scott has entered six drugs into clinical trials. The FDA has also approved applications for three drugs that Scott has been involved in. At the moment, he chairs the board at Achaogen, Semprus, and Relypsa.
Rocklage has more than 30 U.S. patents to his name. He has also authored or co-authored in more 100 peer-reviewed applications.
Rocklage did his undergraduate studies at California University where he graduated with a Bachelor of Science degree in chemistry. He has a Ph.D. in chemistry from the Massachusetts Institute of Technology. While doing his Ph.D., Scott did research in the Laboratory a famous Nobel Prize winner, Richard R. Schrock.
Scott worked for Nycomed Salutar between 1990 and 1994. From 1992 to 1994, he served as the chief executive officer of Nycomed Interventional. Rocklage then moved on to Cubist Pharmaceuticals in 1994. He worked there as a president and chief executive officer for seven years. Rocklage was the director of Protana between 1994 and 2004 and the director of Achaegon from 2004 to 2015.
Other companies that Scott has served in include Catalytical Pharmaceuticals and Salutar. Just before he moved to 5AM Ventures, he was the chief executive officer and president of Amersham Health.
Scott Rocklage has a wife known as Patty Rocklage. They are both kind givers. Recently, they donated a quarter of a million dollars to assist MIT in renovating their nanotechnology and nano-chemistry lab. The two were given a tour by Professor Bawendi and some of his students. MIT also paid tribute to the two and put up a plaque to honor Scott and his wife. Scott said that offering to pay up the renovation costs were part of his thanks to MIT for giving his professional life and career a foundation.